Vanishing 17-Hydroxyprogesterone Concentrations in 21-Hydroxylase Deficiency

Congenital adrenal hyperplasia (CAH) is a well-known genetic disorder affecting adrenal hormone production. In most cases, elevated 17-hydroxyprogesterone (17-OHP) levels are diagnostic of 21-hydroxylase deficiency. However, a gap remains in understanding why some patients with CAH may develop complete adrenal cortex failure despite normal or undetectable 17-OHP levels later in life. Prior research has shown that CAH typically presents with high 17-OHP concentrations, but this case challenges that assumption. The uncertainty in this patient’s clinical presentation raises questions about the reliability of 17-OHP as a diagnostic marker in later stages of disease. No prior work had resolved how to interpret undetectable 17-OHP in a known CAH patient with adrenal failure symptoms. This gap motivated the investigation of alternative diagnostic approaches and differential diagnoses. The study contributes to the field by highlighting the limitations of relying solely on 17-OHP levels for diagnosing adrenal insufficiency in CAH patients. It also emphasizes the need for a broader differential diagnosis when interpreting unexpected clinical findings.

The aim of this study is to investigate a rare clinical scenario in which a patient with genetically confirmed 21-hydroxylase deficiency developed undetectable 17-OHP levels during childhood despite a diagnosis of CAH. The specific problem addressed is the discrepancy between the expected biochemical profile of CAH and the observed adrenal insufficiency symptoms in this patient. The motivation for the study stems from the need to better understand the limitations of using 17-OHP as a sole diagnostic marker in CAH patients. The researchers sought to explore alternative explanations for the patient’s adrenal failure, including autoimmune adrenalitis. This case highlights the importance of considering other causes of adrenal insufficiency in patients with a history of CAH. The study also aims to emphasize the potential for treatment masking to delay diagnosis in such cases. By presenting this case, the authors hope to raise awareness among clinicians about the need for a comprehensive differential diagnosis in patients with CAH who develop adrenal insufficiency symptoms.

The study involved a detailed clinical and biochemical evaluation of a male patient with genetically confirmed 21-hydroxylase deficiency. The researchers monitored 17-hydroxyprogesterone (17-OHP) levels over time and observed a decline to undetectable levels during the second year of life. They also conducted an ACTH stimulation test to assess adrenal function and found no increase in 17-OHP. The patient’s hydrocortisone dosage was gradually reduced, but this did not restore 17-OHP levels. The researchers analyzed ACTH levels and found them to be elevated after hydrocortisone withdrawal, indicating adrenal insufficiency. They considered a range of differential diagnoses for complete adrenal cortex failure, including autoimmune adrenalitis, adrenoleukodystrophy, and adrenal hemorrhage. The study relied on clinical observation, biochemical testing, and a literature-based differential diagnosis approach. The findings were interpreted in the context of known genetic and acquired causes of adrenal insufficiency.

The most significant finding is the undetectable 17-OHP levels in a patient with confirmed 21-hydroxylase deficiency, despite a history of elevated 17-OHP at birth. The patient’s hydrocortisone dose was reduced to approximately 7 mg/m2/day, but this did not restore 17-OHP concentrations. ACTH levels increased after hydrocortisone withdrawal, suggesting complete adrenal cortex failure. The ACTH stimulation test confirmed the absence of adrenal response. The researchers proposed autoimmune adrenalitis as the most likely cause of adrenal insufficiency in this case. Other potential causes, such as adrenoleukodystrophy and adrenal hemorrhage, were considered but not confirmed. The patient’s clinical presentation masked the typical symptoms of adrenal insufficiency due to ongoing CAH treatment. The findings suggest that 17-OHP may not be a reliable marker in later stages of CAH when adrenal failure occurs.

The authors suggest that undetectable 17-OHP levels in a patient with CAH may indicate an alternative cause of adrenal insufficiency rather than a resolution of the disease. The most likely diagnosis in this case is autoimmune adrenalitis, although it is difficult to confirm years after onset. The study highlights the limitations of relying solely on 17-OHP levels for diagnosing adrenal insufficiency in CAH patients. The findings suggest that treatment for CAH may mask the classical symptoms of adrenal insufficiency, leading to delayed diagnosis. The authors propose that clinicians should consider a broader differential diagnosis when evaluating CAH patients with adrenal insufficiency symptoms. The study emphasizes the importance of ACTH levels and stimulation tests in confirming adrenal function. The case underscores the need for a comprehensive approach to diagnosing adrenal insufficiency in patients with a history of CAH. The authors conclude that this case adds to the understanding of the complex interplay between genetic and acquired adrenal disorders.